DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY

Executive Summary

• Devonian Health Group reported statistically significant anti‑fibrotic activity of Thykamine™ in a bleomycin‑induced mouse model of idiopathic pulmonary fibrosis (IPF), outperforming the benchmark drug pirfenidone.
• The most robust efficacy was observed at the 0.5 mg/kg dose, which reduced lung wet weight, tissue index, and multiple histopathological scores versus vehicle controls.
• Gene‑expression analysis showed down‑regulation of key collagen and inflammatory markers (Fn1, Col1a1, Col3a1, etc.) and favorable modulation of matrix metalloproteinases, supporting a disease‑modifying mechanism.

Key Details

• Study Design: Oral administration of Thykamine™ at 0.05, 0.1, 0.25, 0.5, and 1 mg/kg; pirfenidone comparator at 220 mg/kg; 21‑day treatment period in bleomycin‑induced pulmonary fibrosis mice.
• Primary Endpoints: Lung wet weight, lung tissue index, Ashcroft fibrosis score, inflammation score, collagen content, and histopathology.
• Efficacy Results:
• At 0.5 mg/kg, Thykamine™ significantly reduced lung wet weight and tissue index versus bleomycin/vehicle (p < 0.05).
• Significant reductions in Ashcroft fibrosis scores and inflammation scores compared with vehicle; pirfenidone did not achieve statistical significance on these endpoints.
• Molecular Findings:
• Down‑regulated genes: Fn1, Col1a1, Col3a1, Col6a1, Col6a3, Birc5, Ccl2, Cxcl2.
• Up‑regulated gene: Mmp9; down‑regulated Mmp13 – indicating enhanced matrix turnover and reduced progressive injury.
• Dose‑Response: Demonstrated clear dose‑responsive anti‑fibrotic effect across multiple translational endpoints.
• Future Plans: Data to be presented in an upcoming scientific publication; further development of Thykamine™ as a multi‑indication, disease‑modifying platform is anticipated.

Notable Quotes

“These results represent a major inflection point for Thykamine™,” said Dr. André P. Boulet, PhD, CEO. “The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model, but also significantly broaden Thykamine™'s mechanism of action…”.